ContactCredit ReportFinancialsPeopleOwnershipLatest ActivityMutual CompaniesDocumentsRepayment History

Cell And Gene Therapy Catapult

Cell And Gene Therapy Catapult is an active company incorporated on 19 February 2016 with the registered office located in London, Greater London. Cell And Gene Therapy Catapult was registered 9 years ago.
Status
Active
Active since 7 years ago
Company No
10016023
Private Limited Company by guarantee without share capital, use of 'Limited' exemption
Age
9 years
Incorporated 19 February 2016
Size
Micro
Turnover is under £1M
Balance sheet is under £500,000
Under 10 employees
Confirmation
Submitted
Dated 3 February 2025 (9 months ago)
Next confirmation dated 3 February 2026
Due by 17 February 2026 (3 months remaining)
Last change occurred 8 years ago
Accounts
Due Soon
For period 1 Mar28 Feb 2024 (12 months)
Accounts type is Total Exemption Full
Next accounts for period 28 February 2025
Due by 30 November 2025 (28 days remaining)
Address
12th Floor Tower Wing Guy's Hospital
Great Maze Pond
London
SE1 9RT
United Kingdom
Same address since incorporation
Telephone
020 37289500
Email
Unreported
People
Officers
1
Shareholders
-
Controllers (PSC)
2
Director • Chief Executive Officer • British • Lives in England • Born in Jun 1966
Cell Therapy Catapult Limited
PSC
Mr Matthew Brian Durdy
PSC • British • Lives in UK • Born in Jun 1966
Shareholders, PSCs & Group Structure
See who truly controls a company with full PSC, Shareholder, and Group Structure exploration
Mutual Companies
Parkinson's Disease Society Of The United Kingdom
Matthew Brian Durdy is a mutual person.
Active
Aught Limited
Matthew Brian Durdy is a mutual person.
Active
Cell Therapy Catapult Limited
Matthew Brian Durdy is a mutual person.
Active
Cell Therapy Catapult Services Limited
Matthew Brian Durdy is a mutual person.
Active
Parkinson's Research Ventures Limited
Matthew Brian Durdy is a mutual person.
Active
CGTC Manufacturing Innovation Centre Limited
Matthew Brian Durdy is a mutual person.
Active
Financials
Net Assets, Total Assets & Total Liabilities (2017–2024)
Period Ended
28 Feb 2024
For period 28 Feb28 Feb 2024
Traded for 12 months
Cash in Bank
Unreported
Same as previous period
Turnover
Unreported
Same as previous period
Employees
Unreported
Same as previous period
Total Assets
£0
Same as previous period
Total Liabilities
£0
Same as previous period
Net Assets
£0
Same as previous period
Debt Ratio (%)
Unreported
Latest Activity
Confirmation Submitted
9 Months Ago on 3 Feb 2025
Full Accounts Submitted
1 Year 1 Month Ago on 11 Sep 2024
Confirmation Submitted
1 Year 9 Months Ago on 5 Feb 2024
Full Accounts Submitted
2 Years 1 Month Ago on 4 Sep 2023
Confirmation Submitted
2 Years 8 Months Ago on 13 Feb 2023
Full Accounts Submitted
3 Years Ago on 1 Oct 2022
Confirmation Submitted
3 Years Ago on 3 Feb 2022
Full Accounts Submitted
3 Years Ago on 18 Nov 2021
Confirmation Submitted
4 Years Ago on 6 Apr 2021
Full Accounts Submitted
4 Years Ago on 16 Feb 2021
Get Credit Report
Discover Cell And Gene Therapy Catapult's Credit Score, how much credit you can offer them, and how likely they are to repay you
Documents
Confirmation statement made on 3 February 2025 with no updates
Submitted on 3 Feb 2025
Total exemption full accounts made up to 28 February 2024
Submitted on 11 Sep 2024
Confirmation statement made on 3 February 2024 with no updates
Submitted on 5 Feb 2024
Total exemption full accounts made up to 28 February 2023
Submitted on 4 Sep 2023
Confirmation statement made on 3 February 2023 with no updates
Submitted on 13 Feb 2023
Total exemption full accounts made up to 28 February 2022
Submitted on 1 Oct 2022
Confirmation statement made on 3 February 2022 with no updates
Submitted on 3 Feb 2022
Total exemption full accounts made up to 28 February 2021
Submitted on 18 Nov 2021
Confirmation statement made on 18 February 2021 with no updates
Submitted on 6 Apr 2021
Total exemption full accounts made up to 28 February 2020
Submitted on 16 Feb 2021
Repayment History
Understand how businesses repay their debts and see how they're performing year‐on‐year